Comparative Pharmacology
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE versus AZMACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE versus AZMACORT.
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE vs AZMACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azelastine is a histamine H1-receptor antagonist that inhibits histamine release from mast cells; fluticasone propionate is a corticosteroid that suppresses inflammatory mediators including cytokines, prostaglandins, and leukotrienes, reducing nasal inflammation.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
1 spray per nostril twice daily (137 mcg azelastine hydrochloride and 50 mcg fluticasone propionate per spray).
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
None Documented
None Documented
Azelastine: ~25 hours (range 22-27 h). Fluticasone propionate: ~7.8 hours intranasal; 7-8 hours IV; context: intranasal dosing achieves steady-state in 1-2 weeks.
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Azelastine: 75% renal (as unchanged drug and metabolites), 25% fecal. Fluticasone propionate: primarily fecal after IV (90%), renal <5%; after intranasal, significant first-pass hepatic metabolism to inactive metabolites excreted in bile and feces.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Category A/B
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid